BioTrinity 2018: Bullish M&A And IPO Outlook; Spotlight On Eyevensys, Rexgenero
Executive Summary
Industry experts, investors and start-ups from across the pharma, biotech and medtech sectors gathered at the recent annual BioTrinity conference held in London to hear how the capital-raising climate is looking rosy for 2018, and to explore partnering and investment opportunities. Medtech Insight reports on predicted trends in health care and highlights two companies, Eyevensys and Rexgenero, that were presenting at the conference.
You may also be interested in...
Upsized Offerings Boost Medtech IPO Uptick
The public markets are receptive to medtech stock, with the first half of this year recording more – and bigger – medtech IPOs than a year ago.
VC Deals Analysis: Positive Exit Markets Keep Venture Investment Swell Growing
Big-buck rounds of over $100m seem to be becoming the standard – rather than one-offs – in the medtech venture financing scene, with yet another two of these nine-figure transactions recorded in April. These mega rounds, together with the healthy deal volume seen that month, boosted total deal value to nearly $700m.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.